harvardbioscience.com (HBIO) - Cumulative Company Assets

The market value dynamics of Harvard Bioscience (HBIO) on the GURU.Markets platform, which currently stands at 78.15, highlight the scaling potential through the production of unique, high-margin laboratory equipment. The business relies on supplying cell analysis tools to global universities and biopharma behemoths, ensuring resilience against patent risks. Long-term subscriptions for electrophysiological instruments and pumps guarantee a stable cash flow.

Harvard Bioscience Inc. (HBIO) Company Total Assets: for the period 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for Harvard Bioscience (HBIO)

- price and consensus price forecast:

Market Price Harvard Bioscience Inc.|HBIO - Price Target Chart

- market capitalization data:

Market Valuation Harvard Bioscience, Inc.|HBIO - Enterprise Value

- book capitalization data:

Net Asset Value per Share Harvard Bioscience|HBIO - Book Capitalization|Capitalization to Book Value Ratio harvardbioscience.com|HBIO - Company Total Assets

- debt and liquidity data:

Total Debt to Capital Coefficient Harvard Bioscience|HBIO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio harvardbioscience.com|HBIO - Company Aggregate Debts|Debts to Book Capitalization Harvard Bioscience, Inc.|HBIO - Company Long-Term Debt|Company Short-Term Debt Harvard Bioscience

Fundamental valuation:Harvard Bioscience Inc., HBIO

Manufactured product of Harvard Bioscience, Inc.

Total assets, reverse-calculated via ROA, reflect the dynamics of the company's aggregate resources, allowing investors to identify hidden cycles of capital expansion and contraction. By analyzing the changes in the financial assets of Harvard Bioscience (HBIO), one can assess the resilience of its B2B model, where the material base for producing biological research tools provides the foundation for long-term contracts with universities and pharma behemoths.

Main competitors